文献速递胸部肿瘤支持与姑息治疗

早期骨骼肌丢失与奥希替尼谷浓度及疗效的关联

Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.
PubMed 文献 · Eur J Cancer · 2026-04-12

本研究基于START-TKI生物标志物研究,纳入53例晚期EGFR突变NSCLC患者,评估奥希替尼治疗前三个月CT来源的骨骼肌指数(SMI)丢失与奥希替尼谷浓度(Ctrough)及生存结局的关联。结果显示SMI丢失与奥希替尼暴露无关,但为更短总生存(OS)的独立预测因素。

要点

  • 56%的患者在奥希替尼治疗三个月内出现SMI丢失。
  • SMI丢失与奥希替尼Ctrough随时间无关联(β=-17.3;95%CI -59.9-25.2;P=0.42)。
  • SMI丢失是更短OS的独立预测因素(aHR 2.04;95%CI 1.02-4.09;P=0.045)。

核心结论

  • 早期SMI丢失与奥希替尼暴露无关,但为更短OS的独立预测因素。

研究设计与样本

  • 研究纳入2016年1月至2022年1月起始奥希替尼治疗的53例晚期EGFR突变NSCLC患者,来自START-TKI生物标志物研究。
  • 采用线性混合效应模型评估SMI丢失与奥希替尼Ctrough的关联,采用Cox比例风险模型评估PFS和OS。

主要发现

  • 53例患者中27例(56%)在三个月后出现SMI丢失。
  • 前三个月奥希替尼Ctrough中位值为212 ng/mL(IQR 159-279 ng/mL)。
  • 线性混合效应模型显示SMI丢失与奥希替尼Ctrough随时间无关联(β=-17.3;95%CI -59.9-25.2;P=0.42)。
  • SMI丢失与PFS无关(中位PFS 11.5 vs. 11.8个月,HR 0.99 [95%CI 0.56-1.76];P=0.99)。
  • 调整Ctrough和TP53突变状态后,SMI丢失是更短OS的独立预测因素(中位OS 25.5 vs. 29.8个月,aHR 2.04 [95%CI 1.02-4.09];P=0.045)。

关键数值与推荐

  • SMI丢失定义为骨骼肌指数降低≥1.3%。
  • Ctrough最高四分位组和EGFR外显子21 L858R突变患者PFS更短。

临床怎么用

  • 奥希替尼治疗早期出现SMI丢失提示OS可能更短,应关注营养干预以保留肌肉量。
  • SMI丢失与奥希替尼暴露无关,提示其非药物浓度驱动,需综合管理。

局限性

  • 样本量较小(53例),结果需更大样本验证。
  • 研究为观察性设计,无法确定因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study explores the associations between computed tomography (CT)-derived changes in body composition during the first three months of osimertinib monotherapy, systemic osimertinib exposure, and treatment outcomes in patients with advanced EGFR+ NSCLC. MATERIALS AND METHODS: Patients initiating osimertinib between January 2016 and January 2022 were selected from the START-TKI biomarker study. Osimertinib trough concentrations (Ctrough) were quantified. Body composition was assessed on baseline and three-month CT images using SliceOmatic. Loss of skeletal muscle index (SMI) was defined as a reduction of ≥ 1.3%. Associations between SMI loss and osimertinib Ctrough were estimated using linear mixed-effects modeling, while progression-free survival (PFS) and overall survival (OS) were evaluated using Cox proportional hazards models. RESULTS: Fifty-three patients were included. Twenty-seven patients (56%) experienced SMI loss after three months. Median osimertinib Ctrough in the first three months was 212 ng/mL (IQR 159-279 ng/mL). Linear mixed-effects modeling indicated no association between SMI loss and osimertinib Ctrough over time (β = -17.3; 95% CI, -59.9-25.2; P = 0.42). Median follow-up was 53 months (95% CI, 46 - not reached). SMI loss was not associated with PFS (median PFS 11.5 vs. 11.8 months, HR: 0.99 [95% CI, 0.56-1.76]; P = 0.99). Patients in the highest-quartile Ctrough and those with EGFRexon21 L858R mutations had shorter PFS. SMI loss was an independent predictor of shorter OS (median OS 25.5 vs. 29.8 months, aHR: 2.04 [95% CI, 1.02-4.09]; P = 0.045) after adjusting for Ctrough and TP53 mutation status. CONCLUSION: Early loss of SMI was not associated with osimertinib exposure, yet an independent predictor of shorter OS. Future research should explore whether nutritional interventions to preserve muscle mass improve osimertinib effectiveness.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sikkema BJ, Veerman M, Hoop EO, et al. Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC. Eur J Cancer. 2026. PMID: 41997038. doi:10.1016/j.ejca.2026.116742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。